LU91381I2 - OPTAFLU-Définition du produit: Vaccin grippal préparé à partir du virus de la grippe dans une culture celluluaire ou les cellules sont cultivées à unetempérature comprise entre 30°C et 36°C pour la r éplication des virus - Google Patents

OPTAFLU-Définition du produit: Vaccin grippal préparé à partir du virus de la grippe dans une culture celluluaire ou les cellules sont cultivées à unetempérature comprise entre 30°C et 36°C pour la r éplication des virus

Info

Publication number
LU91381I2
LU91381I2 LU91381C LU91381C LU91381I2 LU 91381 I2 LU91381 I2 LU 91381I2 LU 91381 C LU91381 C LU 91381C LU 91381 C LU91381 C LU 91381C LU 91381 I2 LU91381 I2 LU 91381I2
Authority
LU
Luxembourg
Prior art keywords
replication
cell culture
viruses
optaflu
cultured
Prior art date
Application number
LU91381C
Other languages
English (en)
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7790127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91381(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Publication of LU91381I2 publication Critical patent/LU91381I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
LU91381C 1996-04-01 2007-11-30 OPTAFLU-Définition du produit: Vaccin grippal préparé à partir du virus de la grippe dans une culture celluluaire ou les cellules sont cultivées à unetempérature comprise entre 30°C et 36°C pour la r éplication des virus LU91381I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19612967A DE19612967A1 (de) 1996-04-01 1996-04-01 Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
PCT/IB1997/000404 WO1997037001A1 (fr) 1996-04-01 1997-04-01 Procedes de replication des virus de la grippe dans une culture cellulaire, et virus de la grippe obtenus selon ce procede

Publications (1)

Publication Number Publication Date
LU91381I2 true LU91381I2 (fr) 2008-01-30

Family

ID=7790127

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91381C LU91381I2 (fr) 1996-04-01 2007-11-30 OPTAFLU-Définition du produit: Vaccin grippal préparé à partir du virus de la grippe dans une culture celluluaire ou les cellules sont cultivées à unetempérature comprise entre 30°C et 36°C pour la r éplication des virus

Country Status (12)

Country Link
US (2) US20030119183A1 (fr)
EP (3) EP1526172B1 (fr)
JP (6) JP4447054B2 (fr)
AT (2) ATE513905T1 (fr)
CA (1) CA2250078C (fr)
DE (3) DE19612967A1 (fr)
DK (2) DK1526172T3 (fr)
ES (3) ES2236799T5 (fr)
LU (1) LU91381I2 (fr)
NL (1) NL300307I1 (fr)
PT (2) PT1526172E (fr)
WO (1) WO1997037001A1 (fr)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
AU737705B2 (en) * 1997-10-31 2001-08-30 Merck Sharp & Dohme Corp. A method of improved mixing in roller bottles
WO1999023206A1 (fr) * 1997-10-31 1999-05-14 Merck & Co., Inc. Procede de melange ameliore d'une culture cellulaire infectee par la varicelle dans une bouteille pour agitateur rotatif
FR2775601B1 (fr) * 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
CA2401117C (fr) 2000-03-03 2010-06-29 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cellule utilisable pour culture sans serum et culture en suspension, et procede de production de virus pour vaccin utilisant cette cellule
DE10144906B4 (de) * 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
BR0214280A (pt) * 2001-11-19 2005-01-11 Becton Dickinson Co Composição farmacêuticas em forma particulada
US20060019375A1 (en) * 2002-09-16 2006-01-26 Josef Seidl Device for culturing cells, particularly human or animal cells
DE50211123D1 (de) 2002-09-16 2007-12-06 Pan Biotech Gmbh Verfahren zur kultivierung von zellen, insbesondere menschlicher oder tierischer zellen
AU2004249802B2 (en) 2003-06-20 2007-06-28 Microbix Biosystems Inc. Improvements in virus production
US20080254065A1 (en) 2004-03-09 2008-10-16 Chiron Corporation Influenza Virus Vaccines
AU2005245943A1 (en) * 2004-05-20 2005-12-01 Id Biomedical Corporation Process for the production of an influenza vaccine
US20090104226A1 (en) 2004-05-21 2009-04-23 Novartis Vaccines And Diagnostics Inc. Alphavirus Vectors for Respiratory Pathogen Vaccines
RS51665B (sr) * 2004-09-09 2011-10-31 Novartis Vaccines And Diagnostics Gmbh. Smanjenje potencijalnih jatrogenih rizika povezanih sa vakcinama protiv gripa
US7510719B2 (en) 2004-12-08 2009-03-31 Medimmune, Llc Methods of producing influenza vaccine compositions
ES2526170T3 (es) 2004-12-23 2015-01-07 Medimmune, Llc Línea celular MDCK no tumorigénica para propagar virus
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
ATE494906T1 (de) 2005-11-01 2011-01-15 Novartis Vaccines & Diagnostic Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
WO2007052055A1 (fr) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Vaccins avec adjuvant comprenant des antigenes sans virions prepares a partir de virus influenza eleves en culture cellulaire
CA2628424A1 (fr) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Vaccins influenza avec adjuvant comprenant des agents d'induction de cytokines
NZ594482A (en) 2005-11-04 2012-11-30 Novartis Vaccines & Diagnostic Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
ES2377884T3 (es) 2005-11-04 2012-04-02 Novartis Vaccines And Diagnostics S.R.L. Vacunas contra la gripe que incluyen combinaciones de adyuvantes particulados e inmunopotenciadores
KR20080069232A (ko) 2005-11-04 2008-07-25 노바티스 백신즈 앤드 다이아그노스틱스 에스.알.엘. 스플리트 인플루엔자 백신에 대한 보조제로서 유리 수성상계면활성제를 갖는 에멀젼
PL2478916T3 (pl) 2006-01-27 2020-11-16 Seqirus UK Limited Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
WO2007110776A1 (fr) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Stockage de vaccins antigrippaux sans refrigeration
JP2009532352A (ja) 2006-03-31 2009-09-10 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ワクチンのための高力価組み換えインフルエンザ・ウィルス
EP2022849A4 (fr) * 2006-05-11 2010-10-06 Chemo Sero Therapeut Res Inst Procédé permettant une prolifération du virus de la grippe
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
NZ575271A (en) 2006-09-11 2011-09-30 Novartis Ag Making influenza virus vaccines without using eggs
AU2007347716B2 (en) 2006-09-15 2013-06-20 Medimmune, Llc MDCK cell lines supporting viral growth to high titers and bioreactor process using the same
JP2011506264A (ja) 2006-12-06 2011-03-03 ノバルティス アーゲー インフルエンザウイルスの４つの株に由来する抗原を含むワクチン
EP2155863B1 (fr) * 2007-05-04 2014-08-13 Baxter International Inc. Profil de températures en deux étapes pour la propagation de virus
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
PT2185191E (pt) 2007-06-27 2012-11-27 Novartis Ag Vacinas contra a gripe com baixo teor de aditivos
JP5518041B2 (ja) 2008-03-18 2014-06-11 ノバルティス アーゲー インフルエンザウイルスワクチン抗原の調製における改良
CN102216450B (zh) 2008-09-24 2014-05-14 米迪缪尼有限公司 培养细胞、增殖和纯化病毒的方法
JP2012517416A (ja) 2009-02-10 2012-08-02 ノバルティス アーゲー 増加した量のｈ３抗原を含むインフルエンザワクチン
WO2010092476A1 (fr) 2009-02-10 2010-08-19 Novartis Ag Régimes de vaccin antigrippal pour souches liées à une pandémie
EA023662B1 (ru) 2009-02-10 2016-06-30 Новартис Аг Вакцины против гриппа со сниженным количеством сквалена
DE102010018462A1 (de) 2009-04-27 2011-04-07 Novartis Ag Impfstoffe zum Schutz gegen Influenza
JP5836266B2 (ja) 2009-05-21 2015-12-24 ノバルティス アーゲー 非内因性ｐｏｌＩプロモーターを使用した逆遺伝学
WO2010144797A2 (fr) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Vaccins contre la grippe avec immunogénicité accrue et leurs utilisations
WO2011012999A1 (fr) 2009-07-31 2011-02-03 Novartis Ag Systemes de genetique inverse
CN102695523A (zh) 2009-09-10 2012-09-26 诺华有限公司 针对呼吸道疾病的组合疫苗
KR20120083480A (ko) 2009-10-20 2012-07-25 노파르티스 아게 바이러스 구제를 위한 개선된 역유전학 방법
JP2013507990A (ja) 2009-10-26 2013-03-07 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ベロ細胞において増強された複製を有する高力価の組換えインフルエンザウイルス
WO2011095596A1 (fr) 2010-02-04 2011-08-11 Vivalis Procédé à alimentation discontinue utilisant un milieu de culture de cellules concentré pour la production efficace de produits biologiques dans des cellules eb66
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
WO2011139717A1 (fr) 2010-04-26 2011-11-10 Novartis Ag Production améliorée de particules de réplicon de virus dans des cellules d'encapsidation
JP5876036B2 (ja) 2010-05-21 2016-03-02 ノバルティス アーゲー インフルエンザウイルス再集合方法
PL2575872T3 (pl) 2010-06-01 2021-02-22 Seqirus UK Limited Zatężanie antygenów szczepionkowych grypy bez liofilizacji
CA2801151A1 (fr) 2010-06-01 2011-12-08 Novartis Ag Concentration d'antigenes de vaccin par lyophilisation
CA2808965C (fr) 2010-08-20 2020-01-07 Theraject, Inc. Ensembles d'aiguilles solubles pour l'administration de vaccins contre la grippe
KR102266691B1 (ko) 2010-10-11 2021-06-23 노파르티스 아게 항원 전달 플랫폼
ES3018416T3 (es) 2011-01-26 2025-05-16 Glaxosmithkline Biologicals Sa Régimen de inmunización del VRS
EP2686423A4 (fr) 2011-03-14 2015-01-28 Nat Res Council Canada Procédé de production virale dans des cellules
ES2655051T3 (es) 2011-08-26 2018-02-16 Wisconsin Alumni Research Foundation Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas
BR112014008694A2 (pt) 2011-10-11 2017-06-20 Novartis Ag moléculas de ácido nucleico policistrônico recombinante
US20140348863A1 (en) 2011-10-12 2014-11-27 Alessia Bianchi Cmv antigens and uses thereof
EP2768528A1 (fr) 2011-10-20 2014-08-27 Novartis AG Vaccins avec adjuvant contre le virus grippal b pour primo-vaccination pédiatrique
WO2013087945A2 (fr) 2012-03-02 2013-06-20 Novartis Ag Réassortiment du virus de la grippe
CN104159608A (zh) 2012-03-06 2014-11-19 克鲁塞尔荷兰公司 针对流感的改善的疫苗接种
WO2013182498A1 (fr) 2012-06-04 2013-12-12 Novartis Ag Test de sécurité amélioré
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
US9708585B2 (en) 2012-12-03 2017-07-18 Seqirus UK Limited Influenza virus reassortment
CA2905612A1 (fr) 2013-03-13 2014-09-18 Novartis Ag Reassortiment du virus grippal
JP2016521282A (ja) 2013-05-10 2016-07-21 ノバルティス アーゲー インフルエンザワクチンにおけるナルコレプシーのリスクの回避
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
CN105722976A (zh) 2013-06-06 2016-06-29 诺华股份有限公司 流感病毒重配
JP2016524915A (ja) 2013-07-15 2016-08-22 ウィスコンシン アルムニ リサーチ ファンデイション Ｍｄｃｋ、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
AR102547A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
AR102548A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
KR20180035807A (ko) 2015-06-26 2018-04-06 세퀴러스 유케이 리미티드 항원적으로 매치된 인플루엔자 백신
WO2017007839A1 (fr) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Réplication améliorée du virus de la grippe pour l'élaboration de vaccin
AU2016290603B2 (en) 2015-07-07 2022-06-02 Seqirus UK Limited Influenza potency assays
JP2019510481A (ja) 2016-02-19 2019-04-18 ウィスコンシン アルムニ リサーチ ファンデイション ワクチン開発のための改善されたｂ型インフルエンザウイルス複製
WO2019084310A1 (fr) 2017-10-25 2019-05-02 Yoshihiro Kawaoka Virus de la grippe recombinants à ha stabilisé pour la réplication dans des oeufs
MY202505A (en) 2017-11-03 2024-05-01 Takeda Vaccines Inc Zika vaccines and immunogenic compositions, and methods of using the same
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
US11389523B2 (en) 2018-08-20 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
EP3914295A2 (fr) 2019-01-23 2021-12-01 Yoshihiro Kawaoka Mutations conférant une stabilité génétique à des gènes supplémentaires dans des virus de la grippe
WO2020163804A1 (fr) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Lignée cellulaire humanisée
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
AU2020269164B2 (en) 2019-05-08 2024-04-04 Takeda Vaccines, Inc. Inactivated virus compositions and Zika vaccine formulations
WO2021041624A2 (fr) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Virus de la grippe recombinants à ha stabilisé pour réplication dans des oeufs
EP4061930A1 (fr) 2019-11-18 2022-09-28 Seqirus Pty Ltd Procédé de production de virus de la grippe réassortis
JP2023511444A (ja) 2020-01-24 2023-03-17 ウィスコンシン アルムニ リサーチ ファンデイション 安定化されたｎａを有する組換えインフルエンザウイルス
WO2021195410A1 (fr) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Virus de la grippe multivalents recombinants
KR102444684B1 (ko) * 2020-04-29 2022-09-16 에스케이바이오사이언스(주) 일회용 배양 공정 시스템을 이용한 인플루엔자 바이러스 생산 방법
US20250381261A1 (en) 2022-02-09 2025-12-18 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1278075B (de) * 1964-06-22 1968-09-19 Norden Lab Inc Verwendung von Gewebekulturen zur Zuechtung von Viren fuer die Gewinnung von Impfstoffen
US4064232A (en) * 1974-01-14 1977-12-20 Sandoz Ltd. Process for isolating the immunogenic components of influenza viruses
US4500513A (en) * 1979-05-15 1985-02-19 Miles Laboratories, Inc. Influenza vaccine production in liquid cell culture
CA1122527A (fr) * 1979-05-15 1982-04-27 Karen K. Brown Production d'un vaccin contre l'influenza par culture de cellules en milieu liquide
USRE33164E (en) * 1979-05-15 1990-02-13 Mobay Corporation Influenza vaccine production in liquid cell culture
US5013663A (en) * 1983-06-15 1991-05-07 American Home Products Corporation Canine corona virus vaccine
US4783411A (en) * 1984-10-22 1988-11-08 Janis Gabliks Influenza-A virus vaccine from fish cell cultures
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
US5824536A (en) * 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
US5753489A (en) * 1994-11-10 1998-05-19 Immuno Ag Method for producing viruses and vaccines in serum-free culture
US5756341A (en) * 1994-11-10 1998-05-26 Immuno Ag Method for controlling the infectivity of viruses
US5646033A (en) * 1994-11-30 1997-07-08 Dyncorp African green monkey kidney cell lines useful for maintaining viruses and for preparation of viral vaccines
DE19612966B4 (de) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
US6514502B1 (en) * 1999-01-26 2003-02-04 Schering-Plough Veterinary Corporation Propagation of bovine cononavirus in chinese hamster ovary cells

Also Published As

Publication number Publication date
NL300307I1 (nl) 2008-02-01
ES2435726T3 (es) 2013-12-23
HK1075467A1 (en) 2005-12-16
EP0891420B1 (fr) 2005-02-02
PT891420E (pt) 2005-06-30
WO1997037001A1 (fr) 1997-10-09
EP2172543B1 (fr) 2013-08-21
US20030119183A1 (en) 2003-06-26
EP0891420A1 (fr) 1999-01-20
EP1526172A1 (fr) 2005-04-27
ES2236799T3 (es) 2005-07-16
PT1526172E (pt) 2011-09-01
US20070117131A1 (en) 2007-05-24
ES2236799T5 (es) 2014-01-23
JP5264843B2 (ja) 2013-08-14
DK0891420T3 (da) 2005-04-25
EP0891420B2 (fr) 2013-11-20
DE122007000082I1 (de) 2009-01-02
CA2250078A1 (fr) 1997-10-09
DE19612967A1 (de) 1997-10-02
JP2000507825A (ja) 2000-06-27
ATE288479T1 (de) 2005-02-15
HK1142093A1 (en) 2010-11-26
JP2010275321A (ja) 2010-12-09
DE69732407T3 (de) 2014-07-10
ATE513905T1 (de) 2011-07-15
DK0891420T4 (da) 2014-01-20
EP1526172B1 (fr) 2011-06-22
JP2006296437A (ja) 2006-11-02
DE69732407D1 (de) 2005-03-10
CA2250078C (fr) 2009-06-23
EP2172543A1 (fr) 2010-04-07
JP2008245659A (ja) 2008-10-16
ES2367081T3 (es) 2011-10-28
JP4447054B2 (ja) 2010-04-07
DE69732407T2 (de) 2006-01-19
DK1526172T3 (da) 2011-10-03
JP2011212020A (ja) 2011-10-27
JP2013116124A (ja) 2013-06-13

Similar Documents

Publication Publication Date Title
PT1526172E (pt) Processo para a replicação de vírus influenza em cultura celular e os vírus influenza que podem ser obtidos pelo processo
Wagner Reproduction of rhabdoviruses
Germain et al. Inhibition of T-lymphocyte-mediated tumor-specific lysis by alloantisera directed against the H-2 serological specificities of the tumor
EA200200604A1 (ru) Производство вакцин
EP0517792A1 (fr) Peptides antiviraux a terminaisons bloquees
SI1427817T1 (sl) Razmnoževanje virusov in celičnih kultur
ES2139553T1 (es) Replicacion de virus de la gripe en un cultivo de celulas de mamiferos y produccion de vacuna.
Gething et al. Fusion of Sendai virus with the target cell membrane is required for T cell cytotoxicity
Zinkernagel et al. General and specific immunosuppression caused by antiviral T‐cell responses
DK0480949T3 (da) Fremstilling af virus og oprensning af virale kappeproteiner til vaccineanvendelse
Vestergárd Jørgensen Indirect fluorescent antibody techniques for demonstration of trout viruses and corresponding antibody
JPH114685A (ja) 冬眠特異的タンパク質産生樹立細胞株およびその創製方法
Young et al. A foamy virus of possible human origin isolated in BHK-21 cells
BR0307512A (pt) Métodos para produzir uma linhagem de células contìnua, para gerar e/ou isolar e/ou manter uma cepa de vìrus da doença de marek, para produzir um antìgeno diagnóstico de um vìrus da doença de marek, para preparar uma vacina capaz de induzir proteção contra doença em um vertebrado, e para proteger um vertebrado contra doença, célula ou sua prole, preparação de células, uso das mesmas, vacina, e, uso da mesma
DE60143810D1 (de) Vakzine gegen ipnv die aus hefezellen isoliert werden
Miller et al. Monoclonal antibody to Lyt 2 antigen blocks H–2I-and H–2K-specific mouse cytotoxic T cells
RU95117092A (ru) Антитела, смесь антител, fab-фрагмент, линии гибридомных клеток, способы создания линий клеток, способ борьбы с вирусом, способ снижения уровня антигена, днк
DE60124725D1 (de) Herstellung eines chimeren papillomavirus
RU2136747C1 (ru) Способ ингибирования инфекционной активности вируса иммунодефицита человека
Sabesin The Role of Lysosomes in the Pathogenesis of Experimental Viral Hepatitis∗†.
TH35753C3 (th) อิมมูโนเจนที่ถูกเพิ่มกำลัง สำหรับวัคซีนเชื้อตายเพื่อต่อสู้กับโรคที่เป็นการติดเชื้อ ที่มีสาเหตุมาจากกลุ่มของเจเปเนส เอนซีฟาไลทีสไวรัสและวิธีการเพื่อผลิตสิ่งนั้น
Kaneko et al. Cytotoxic T lymphocytes to murine plasmacytoma cells in allogeneic and syngeneic mice: H-2 antigens are essential in the induction and effector stages of CTL
Bell et al. Effect of herpes simplex virus on human embryonic cells latently infected with reovirus type 3
Rossier Studies on the immunogenicity of virus-infected lymphocytes for the production of antilymphocyte serum
Famulari et al. High-titer replication of nondefective Sendai virus in MDBK cells